General Biologicals Corp.

What General Biologicals Corp. does

General Biologicals Corporation (GBC, TWSE: 4117) is a Taiwan-headquartered in-vitro diagnostics (IVD) company founded in 1984, originating from Taiwan's National Hepatitis Prevention Program. The company develops and manufactures diagnostic instruments and reagent kits across four platforms: ELISA immunoassays (HBsAg, HCV, HIV Ag/Ab), chemiluminescence immunoassay (CLIA, headlined by the GBC CL i120 Analyzer with 120–200 tests/hour throughput), molecular diagnostics (GBC AIO M160 All-in-One system and GB RealQuant AIO for HBV/HCV/HPV/SARS-CoV-2), and liquid biopsy via the CellBio™ platform using its patented iFiltration™ microfiltration technology (claimed >90% cancer cell capture rate from 7.5mL blood samples).

GBC operates an integrated value chain from R&D through manufacturing to clinical diagnostic services, organized around four revenue streams: Precision Medicine (64% of revenue as of April 2025, anchored by CTC testing services via the Fubon Life Insurance partnership at 70+ blood collection sites in Taiwan), Digital Medical Healthcare Services (17%), Biopharmaceuticals and Health Products (19%, including P113 antimicrobial peptide therapeutics in Phase IIb and the oh care® consumer brand), and CDMO Services. The company sells through direct hospital/laboratory sales in Taiwan, exclusive three-year distributor agreements internationally (notably Brazil covering 40%+ of local blood centers and 200+ labs), and insurance-mediated consumer channels, with products distributed across 40+ countries and over 80 SKUs.

The company's headquarters and primary R&D/manufacturing facility is in Hsinchu Science Park, Taiwan, with a new AI Biotech Building commissioned in May 2025 at AI Smart Park, Hsinchu County, serving as the global hub for AI-driven CTC big data production, macrocyclic peptide drug development, and international CDMO. GBC operates through wholly-owned subsidiaries including CurieMed Corporation (Taiwan digital medical diagnostics), Danner Laboratory Inc. (clinical pathology in USA/Canada), GB Genes Corp. and GB Pharma (P113 peptide therapeutics and consumer health), and acquired Pacgen Life Science in 2020. The company holds ISO 13485 certification, CE marks on ELISA reagents, TFDA approval for the CL i120 (Q4 2024), and has an EU IVDR application in progress.

Name

General Biologicals Corp.

Legal name

General Biologicals Corporation (普生股份有限公司)

Website

https://gbc.com.tw

Company type

Public

Founded year

1984

Operating status

Operating

Headcount range

11–50 employees

Short description

General Biologicals Corporation (TWSE: 4117) is a Taiwan-based in-vitro diagnostics company developing ELISA, CLIA, molecular diagnostic, and liquid biopsy (CTC) platforms alongside P113 antimicrobial peptide therapeutics, serving hospitals, laboratories, and blood banks across 40+ countries.

Ownership category

akta.pro rank

Product category

In-vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151), Analytical Laboratory Instrument Manufacturing (334516), Medical Equipment and Supplies Manufacturing (3391)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

akta.pro secondary industries

Microbiology & Infectious Disease Testing (Trial Support) (HLAGAEAF), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF), Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK)

Keywords

• In-vitro diagnostics
• Molecular diagnostic systems
• Liquid biopsy platforms
• Chemiluminescence immunoassays
• Antimicrobial peptide therapeutics

Headquarters

HQ city

Baoshan

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Precision Diagnostics - Equipment + Reagents: Combined equipment and diagnostic reagent products sales model targeting hospitals, clinics, and laboratories. Equipment sales drive steady demand for proprietary reagents.
2. Diagnostic Services: CTC testing services offered directly to consumers via insurance partnerships. As of April 2025, Precision Medicine segment represents 64% of total revenue.
3. Biopharmaceuticals and Consumer Health Products: P113 antimicrobial peptide drug development and consumer healthcare products under oh care® brand including oral care, baby care, and skin care products. Segment represents 19% of total revenue.
4. CDMO Services: Contract Development and Manufacturing Organization services including macrocyclic peptide drug development and manufacturing, international CDMO services. Segment represents 17% of total revenue.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

General Biologicals Corp. (GBC) develops, manufactures, and globally distributes in-vitro diagnostic (IVD) platforms and consumables — including ELISA, chemiluminescence immunoassay (CLIA), molecular diagnostics (Real-Time PCR), and liquid biopsy/CTC detection systems (CellBio™ with iFiltration™). It also offers P113 antimicrobial peptide therapeutics, oh care® consumer health products, CDMO services, and clinical laboratory testing via its CurieMed and Danner subsidiaries.

Product overview

General Biologicals Corp. offers a comprehensive IVD portfolio spanning multiple diagnostic platforms and product lines. The core offerings include: (1) Molecular Diagnostics — the GBC AIO M160 All-in-One Molecular System and GB RealQuant AIO for automated sample-to-result testing of infectious diseases (HBV, HCV, HPV, SARS-CoV-2); (2) Immunoassay Solutions — ELISA and CLIA platforms including the GBC CL i120 Chemiluminescence Analyzer with 120-200 tests/hour throughput for tumor markers, thyroid function, infectious diseases, and cardiac biomarkers; (3) Liquid Biopsy — the CellBio™ platform comprising FX10 (10-sample capacity) and a2000 CTC detection systems using patented iFiltration™ technology with >90% capture rates; (4) Consumer Healthcare — the oh care® brand featuring P113 antimicrobial peptide products for oral, baby, and skin care; (5) CDMO Services — contract development and manufacturing for diagnostic reagents and biologics. The company serves hospitals, clinical laboratories, blood banks, and consumers across 40+ countries.

Differentiator

Problem solved

Functional benefit

Brands

• oh care: Consumer health brand powered by P113 antimicrobial peptide technology, offering oral care, baby care, and skin care products.
• GB Pharma
• CurieMed
• Danner Lab
• GB Genes
• CellBio

Products and services

• GBC AIO M160 All-in-One Molecular System Fully automated molecular diagnostic platform integrating sample extraction, PCR setup, and Real-Time PCR detection; processes up to 16 samples simultaneously with turnaround under 2.5 hours, with bi-directional LIS integration, for clinical and research laboratories.
• CellBio™ FX10 CTC Detection System Automated circulating tumor cell (CTC) detection system using patented iFiltration™ technology, processing up to 10 samples per run with >90% capture rates, used by hospitals and oncology centers for early cancer detection and monitoring.
• CellBio™ a2000 CTC Detection System High-sensitivity CTC isolation system processing 2 samples at a time, isolating CTCs and CTMs for early cancer detection, recurrence monitoring, and precision oncology applications.
• GBC CL i120 Chemiluminescence Analyzer High-throughput chemiluminescence immunoassay (CLIA) system running 120–200 tests/hour for tumor markers, thyroid function, infectious diseases, hormones, cytokines, and cardiac biomarkers, targeted at hospital and reference laboratories.
• GB COVID-19 Ag POCT

Quantifiable outcome

• Over 90% cancer cell capture rate from 7.5mL blood samples
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• Brazilian DistributorcoreChannel Partner/ Reseller/ Distributor · 1 February 2024Three-year exclusive distribution agreement for South America. Products include ELISA serum antibody assays, hepatitis A/B/C/D testing assays, CLIA chemiluminescence immunoassay and PCR equipment with related reagents. Brazilian distributor has partnerships with over 40% of local blood centers and accumulated sales channels with more than 200 laboratories and hospitals. Deliveries commenced April 2024.
• Fubon Life InsurancecoreGTM or Marketing Partner · 1 January 2021Exclusive partnership offering 'next generation myCTC circulating tumor cell blood testing' and 'Tumor Marker Testing' services to policyholders. Services available at over 70 blood collection sites with test reports within 7 working days. Over 25,000 cases completed as of October 2024, contributing to GBC's precision medicine business growth.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Maccura Biotechnology: China-based IVD company specializing in clinical chemistry, immunoassay, molecular diagnostics, and hematology reagents. Directly comparable to GBC's IVD reagent and equipment business with overlapping hepatitis and infectious disease test menus.
• Sysmex Corporation: Japan-headquartered global leader in hematology, IVD, and clinical laboratory diagnostics. Direct comparable to GBC across immunoassay (HISCL), molecular diagnostics, and Asian-market distribution, with significantly larger scale and product breadth.
• Mindray Bio-Medical Electronics: China-based global IVD and patient monitoring manufacturer with overlapping product portfolio including chemiluminescence immunoassay analyzers, clinical chemistry, and hematology. Competes with GBC across Asian emerging markets and CLIA platforms.
• Autobio Diagnostics: China-based IVD company focused on immunoassay (CLIA), microbiology, and clinical chemistry reagents and instruments. Closely comparable to GBC in CLIA platform offerings and emerging-market distribution strategies.
• Guardant Health: US-based liquid biopsy pioneer focused on circulating tumor DNA and oncology testing. Directly comparable to GBC's CellBio™ CTC platform in the precision oncology liquid biopsy market, though using a different technological approach.
• Hologic: US-based molecular diagnostics and women's health company with strong oncology and infectious disease franchises. Comparable to GBC in molecular diagnostic platforms and HPV/oncology testing focus areas.

Broad incumbents

• Becton, Dickinson and Company (BD): Global medical technology company with significant IVD and microbiology testing franchises (BD MAX, BD FACSChorus). Overlaps with GBC's infectious disease testing, blood screening, and laboratory automation offerings.
• Beckman Coulter (Danaher): Major clinical laboratory instrument and reagent manufacturer within Danaher's diagnostics platform. Directly comparable in immunoassay (Access/DxI), clinical chemistry, and high-throughput hospital laboratory installations.
• Roche Diagnostics: Division of Roche holding the largest global IVD market share across immunoassays (cobas), molecular diagnostics, and clinical chemistry. Broad incumbent with overlapping capabilities to GBC across all major diagnostic segments.
• Abbott Diagnostics: Global diagnostics leader offering immunoassay (ARCHITECT), molecular (Alinity m), and point-of-care platforms. Competes with GBC across the full IVD spectrum, especially in infectious disease and emerging-market expansion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCgLVeXt2nrYTFqTju3h8OQA
• Facebookfacebook.com/GBCTW
• LinkedInlinkedin.com/company/general-biologicals-corp-gbc-

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about General Biologicals Corp.